Tuberin regulates E-cadherin localization: Implications in epithelial-mesenchymal transition

American Journal of Pathology

Volumn 177, Issue 4, 2010, Pages 1765-1778

  Barnes, Elizabeth A ^a   Kenerson, Heidi L ^a   Jiang, Xiuyun ^a   Yeung, Raymond S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; OCCLUDIN; PROTEIN KINASE B; RAPAMYCIN; SMOOTH MUSCLE ACTIN; TRANSCRIPTION FACTOR SNAIL; TUBERIN; UVOMORULIN;

ANOIKIS; ARTICLE; CELL ADHESION; CELL GROWTH; CELL SUSPENSION; CONTROLLED STUDY; EPITHELIUM; GENE MUTATION; HUMAN; HUMAN TISSUE; LYMPHANGIOLEIOMYOMATOSIS; MESENCHYME; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUBEROUS SCLEROSIS;

EID: 77957329131     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090233     Document Type: Article

References (45)

1. Gomez MR: Definition and criteria for diagnosis. Tuberous Sclerosis Complex, ed 3. Edited by MR Gomez, JR Sampson, VH Whittemore. New York, Oxford University Press, 1999, pp. 10-23
2. Inoki K, Li Y, Xu T, Guan KL: Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev 2003, 17:1829-1834
3. Inoki K, Corradetti MN, Guan KL: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005, 37:19-24
4. Tremblay F, Brule S, Hee Um S, Li Y, Masuda K, Roden M, Sun XJ, Krebs M, Polakiewicz RD, Thomas G, Marette A: Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc Natl Acad Sci USA 2007, 104:14056-14061
5. Cheadle JP, Reeve MP, Sampson JR, Kwiatkowski DJ: Molecular genetic advances in tuberous sclerosis. Hum Genet 2000, 107:97-114
6. Carsillo T, Astrinidis A, Henske EP: Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000, 97:6085-6090 (Pubitemid 30367527)
7. Johnson SR, Tattersfield AE: Lymphangioleiomyomatosis. Semin Respir Crit Care Med 2002, 23:85-92
8. Finlay G: The LAM cell: what is it, where does it come from, and why does it grow? Am J Physiol Lung Cell Mol Physiol 2004, 286:L690-L693
9. Folpe AL: Neoplasms with perivascular epitheloid cell differentiation (PEComas). World Health Organization Classification of Tumors. Pathology & Genetics: Tumors of Soft Tissue and Bone. Edited by CDM Fletcher, KK Unni, F Mertens. Lyon, France, IARC Press, 2002, pp. 221-222
10. Henske EP: Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 2003, 38:376-381
11. Goncharova EA, Goncharov DA, Lim PN, Noonan D, Krymskaya VP: Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 2006, 34:473-480
12. Crooks DM, Pacheco-Rodriguez G, DeCastro RM, McCoy JP Jr, Wang JA, Kumaki F, Darling T, Moss J: Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2004, 101:17462-17467
13. Bittmann I, Dose TB, Muller C, Dienemann H, Vogelmeier C, Lohrs U: Lymphangioleiomyomatosis: recurrence after single lung transplantation. Hum Pathol 1997, 28:1420-1423
14. Bittmann I, Rolf B, Amann G, Lohrs U: Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol 2003, 34:95-98
15. Karbowniczek M, Astrinidis A, Balsara BR, Testa JR, Lium JH, Colby TV, McCormack FX, Henske EP: Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003, 167:976-982
16. Krymskaya VP: Smooth muscle like cells in pulmonary lymphangioleiomyomatosis. Proc Am Thorac Soc 2008, 5:119-126
17. Lee JM, Dedhar S, Kalluri R, Thompson EW: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006, 172:973-981
18. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, Thompson EW: Epithelial - mesenchymal and mesenchymal - epithelial transitions in carcinoma progression. J Cell Physiol 2007, 213:374-383
19. 2+ dependence and mutational analysis reveal molecular details of E-cadherin homoassociation. EMBO J 1999, 18:1738-1747
20. Jin F, Wienecke R, Xiao GH, Maize JC Jr, DeClue JE, Yeung RS: Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. Proc Natl Acad Sci USA 1996, 93:9154-9159
21. Jiang X, Yeung RS: Regulation of microtubule-dependent protein transport by the TSC2/mammalian target of rapamycin pathway. Cancer Res 2006, 66:5258-5269
22. Teckchandani A, Toida N, Goodchild J, Henderson C, Watts J, Wollscheid B, Cooper JA: Quantitative proteomics identifies a Dab2/integrin module regulating cell migration. J Cell Biol 2009, 186:99-111
23. Wendeler MW, Praus M, Jung R, Hecking M, Metzig C, Gessner R: Ksp-cadherin is a functional cell-cell adhesion molecule related to LI-cadherin. Exp Cell Res 2004, 294:345-355
24. Fouquet S, Lugo-Martinez VH, Faussat AM, Renaud F, Cardot P, Chambaz J, Pincon-Raymond M, Thenet S: Early loss of E-cadherin from cell-cell contacts is involved in the onset of Anoikis in enterocytes. J Biol Chem 2004, 279:43061-43069
25. Jones KA, Jiang X, Yamamoto Y, Yeung RS: Tuberin is a component of lipid rafts and mediates caveolin-1 localization: role of TSC2 in post-Golgi transport. Exp Cell Res 2004, 295:512-524
26. Jiang X, Kenerson H, Aicher L, Miyaoka R, Eary J, Bissler J, Yeung RS: The tuberous sclerosis complex regulates trafficking of glucose transporters and glucose uptake. Am J Pathol 2008, 172:1748-1756
27. Lu Z, Ghosh S, Wang Z, Hunter T: Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of β-catenin, and enhanced tumor cell invasion. Cancer Cell 2003, 4:499-515
28. Wan X, Harkavy B, Shen N, Grohar P, Helman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007, 26:1932-1940
29. Kumasaka T, Seyama K, Mitani K, Sato T, Souma S, Kondo T, Hayashi S, Minami M, Uekusa T, Fukuchi Y, Suda K: Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol 2004, 28:1007-1016
30. Mak BC, Yeung RS: The tuberous sclerosis complex genes in tumor development. Cancer Invest 2004, 22:588-603
31. Stehbens SJ, Paterson AD, Crampton MS, Shewan AM, Ferguson C, Akhmanova A, Parton RG, Yap AS: Dynamic microtubules regulate the local concentration of E-cadherin at cell-cell contacts. J Cell Sci 2006, 119(Pt 9):1801-1811
32. Mak BC, Takemaru K, Kenerson HL, Moon RT, Yeung RS: The tuberin-hamartin complex negatively regulates β-catenin signaling activity. J Biol Chem 2003, 278:5947-5951
33. Mak BC, Kenerson HL, Aicher LD, Barnes EA, Yeung RS: Aberrant β-catenin signaling in tuberous sclerosis. Am J Pathol 2005, 167:107-116
34. Barnes EA, Kenerson HL, Mak BC, Yeung RS. The loss of tuberin promotes cell invasion through the β-catenin pathway. Am J Respir Cell Mol Biol 2009, DOI: 10.1165/rcmb.2008-0335OC
35. Pla P, Moore R, Morali OG, Grille S, Martinozzi S, Delmas V, Larue L: Cadherins in neural crest cell development and transformation. J Cell Physiol 2001, 189:121-132
36. Lim SD, Stallcup W, Lefkove B, Govindarajan B, Au KS, Northrup H, Lang D, Fisher DE, Patel A, Amin MB, Arbiser JL: Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells? Mol Med 2007, 13:160-165
37. Bonetti F, Pea M, Martignoni G, Zamboni G, Iuzzolino P: Cellular heterogeneity in lymphangiomyomatosis of the lung. Hum Pathol 1991, 22:727-728
38. Baum B, Settleman J, Quinlan MP: Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 2008, 19:294-308
39. Elloul S, Elstrand MB, Nesland JM, Trope CG, Kvalheim G, Goldberg I, Reich R, Davidson B: Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer 2005, 103:1631-1643
40. Shioiri M, Shida T, Koda K, Oda K, Seike K, Nishimura M, Takano S, Miyazaki M: Slug expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Br J Cancer 2006, 94:1816-1822
41. Waldmann J, Feldmann G, Slater EP, Langer P, Buchholz M, Ramaswamy A, Saeger W, Rothmund M, Fendrich V: Expression of the zinc-finger transcription factor Snail in adrenocortical carcinoma is associated with decreased survival. Br J Cancer 2008, 99:1900-1907
42. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, Leonard JM, Schmithorst VJ, Laor T, Brody AS, Bean J, Salisbury S, Franz DN: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008, 358:140-151
43. Krämer S, Wang-Rosenke Y, Scholl V, Binder E, Loof T, Khadzhynov D, Kawachi H, Shimizu F, Diekmann F, Budde K, Neumayer HH, Peters H: Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol 2008, 294:F440-F449
44. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J: Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006, 45:786-796
45. Gao XM, Wong G, Wang B, Kiriazis H, Moore XL, Su YD, Dart A, Du XJ: Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens 2006, 24:1663-1670